The clinical trial proposals of new drugs already approved in other countries, fixed dose combinations (FDCs), subsequent new drugs, vaccines, etc will henceforth be disposed of by the Drugs Controller General of India (DCGI). This practically ... PharmaBiz, 1 day ago
Clinical Trials in India: Approval Process, New Webinar Hosted by Xtalks - Wall Street Select, 1 month ago
India issues new requirements for clinical trial approval - British Medical Journal, 1 month ago
1 images for "dcgi"
The Drugs Controller General of India (DCGI) Dr. GN Singh has directed all the state drug controllers in the country to provide details of the manufacturers of bulk and formulations of oxytocin in their states along with the statistical information ...PharmaBiz, 2 days ago Maha FDA recommends NPPA to bring five categories of medical devices under DPCO PharmaBiz, 3 weeks ago DCGI concludes drive to check quality of medicines in Chhatisgarh PharmaBiz, 3 weeks ago
The Central Drugs Standard Control Organisation (CDSCO) will soon start issuing the mandatory Written Confirmation (WC) certificate to the Indian API exporters to European Union (EU) on providing the 6 months long term stability data against the ...PharmaBiz, 3 days ago Dr S Manivannan, Dy DCGI, takes addl charge of sub-zone CDSCO Bengaluru PharmaBiz, 1 month ago CDSCO forms 5-member panel headed by Dr. Jagashetty to review manpower structure of CDL, Kolkata PharmaBiz, 22 hours ago Indian government takes action over dubious fixed-dose combinations Pharma Letter, 1 month ago
Commerce Ministry is soon expected to call upon a meeting with the Drug Controller General of India (DCGI) and the Pharmaceuticals Export Promotion Council of India (Pharmexcil) in Delhi, to deliberate over the issues raised by exporters during CPhI ...PharmaBiz, 2 weeks ago Pharmexcil to step up interaction between DCGI, DGFT and stakeholders to help exports PharmaBiz, 1 month ago Sensex inches towards 27000; HDFC twins, pharma lead Money Control, 1 month ago TROUBLE WORSENING FOR EXPORTERS PharmaBiz, 1 month ago
The Drug Controller General of India (DCGI) has approved marketing and manufacturing of Remicade (infliximab) biosimilar BOW015 of EPIRUS Biopharmaceuticals, Inc., a Boston-based biopharmaceutical company focused on the global development and ...PharmaBiz, 1 month ago Epirus gets DCGI nod for arthritis drug biosimilar Business Standard, 1 month ago Epirus Remicade Biosimilar Approved in India FDA News, 1 month ago EPIRUS BIOPHARMACEUTICALS : ' Remicade® Biosimilar Receives Final Approvals in India 4 Traders, 1 month ago
Singapore: India's Chennai-based Nichi-In Center for Regenerative Medicine has been by the DCGI, to stop selling the Dendriatic cell cancer vaccine for Dendriatic immunization therapy. The controller has also issued a safety alert against the use of ...Bio Spectrum Asia, 1 month ago DCGI orders Nichi-In to stop sale of Dendriatic cell cancer vaccine in name of Dendriatic cell immunotherapy PharmaBiz, 1 month ago
PUNE: The health department of the Pune Municipal Corporation (PMC) has urged the Food and Drugs Administration (FDA) to ban the sale of rapid diagnostic test kits for dengue, which are primarily used by private hospitals and pathology laboratories ...Times of India, 2 days ago
The Biosciences and Bioengineering departments at IIT Bombay have created two innovative portable diagnostic systems to measure blood sugar and other components. Rohit Srivastava, an associate professor, who has worked on both the projects was ...Mumbai Mirror, 2 days ago
The 2013/14 financial year saw Epistem commence and successfully complete its Indian clinical evaluation study in advance of the planned launch of Genedrive®, its revolutionary handheld molecular diagnostic device, whilst accelerating investment in ...4 Traders, 2 days ago EpiStem : Successful Completion of Genedrive(R) Indian Clinical Trials and Regulatory Submission 4 Traders, 3 days ago Successful Completion of Genedrive(R) Indian Clinical Trials and Regulatory Submission Pharmacy Choice, 3 days ago
Epistem Holdings posts operating losses of £2.3m for the year to the end of June - up from £1.5m last time. Revenue and other income - development grant funding - increased to £5.8m from £5.4m. Separately,the group announced the successful ...TrustNet, 3 days ago
on your WebpageAdd Widget >Get your members hooked!